Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Shi, R; Wang, X; Wu, Y; Xu, B; Zhao, T; Trapp, C; Wang, X; Unger, K; Zhou, C; Lu, S; Buchner, A; Schulz, GB; Cao, F; Belka, C; Su, C; Li, M; Shu, Y.
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
Theranostics. 2022; 12(9): 4181-4199.
Doi: 10.7150/thno.73235
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Zhao Tianyu
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) family-mediated mutagenesis is widespread in human cancers. However, our knowledge of the biological feature and clinical relevance of APOBECs and APOBEC mutagenesis in cancers remains limited. Methods: In this study, with a series of bioinformatic and statistical approaches, we performed a comprehensive analysis of multiple levels of data, including whole-exome sequencing (WES) and targeted next-generation sequencing (NGS), transcriptome (bulk RNA-seq and single-cell RNA-seq), immune signatures and immune checkpoint blockade (ICB) potential, patient survival and drug sensitivity, to reveal the distribution characteristics and clinical significance of APOBECs and APOBEC mutagenesis in pan-cancer especially bladder cancer (BLCA). Results: APOBEC mutagenesis dominates in the mutational patterns of BLCA. A higher enrichment score of APOBEC mutagenesis correlates with favorable prognosis, immune activation and potential ICB response in BLCA patients. APOBEC3A and 3B play a significant role in the malignant progression and cell differentiation within the tumor microenvironment. Furthermore, using machine learning approaches, a prognostic APOBEC mutagenesis-related model was established and validated in different BLCA cohorts. Conclusions: Our study illustrates the characterization of APOBECs and APOBEC mutagenesis in multiple cancer types and highlights its potential value as a promising biomarker for prognosis and immunotherapy in BLCA.
- Find related publications in this database (using NLM MeSH Indexing)
- Cytidine Deaminase - genetics
- Humans - administration & dosage
- Immunotherapy - administration & dosage
- Mutagenesis - administration & dosage
- Proteins - administration & dosage
- Tumor Microenvironment - administration & dosage
- Urinary Bladder Neoplasms - genetics, pathology, therapy